Navigation Links
Shire to Introduce a New UK Listed Holding Company
Date:4/14/2008

not constitute an offer or invitation to purchase securities.

Morgan Stanley & Co International plc is acting for Shire and Shire Limited and no one else in connection with the Proposals and will not be responsible to anyone other than Shire and Shire Limited for the protections afforded to its clients or for providing advice in relation to the Proposals or the content of this announcement.

THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN INVITATION OR OFFER TO SELL OR THE SOLICITATION OF AN INVITATION OR OFFER TO BUY ANY SECURITY. NONE OF THE SECURITIES REFERRED TO IN THIS ANNOUNCEMENT SHALL BE SOLD, ISSUED, EXCHANGED OR TRANSFERRED IN ANY JURISDICTION IN CONTRAVENTION OF APPLICABLE LAWS.

Notice To United States Residents

This announcement is not an offer of securities in the United States.

The Shire Limited ordinary shares to be issued in connection with the Proposals will not be, and are not required to be, registered with the US Securities and Exchange Commission under the US Securities Act of 1933, as amended, in reliance on the exemption from registration provided by Section 3(a)(10) thereof.

The "SAFE HARBOR" Statement Under the Private Securities Litigation Reform Act of 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research; product development including, but not limited to, the successful development of JUVISTA(R) (Human TGFBeta3) and velaglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM)(lisdexamfetamine dimesylate) (Attention Deficit and Hypera
'/>"/>

SOURCE Shire PLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
2. Shire plc: Long Term Incentive Plan
3. Shire plc: IFRS Results for the Year Ending December 31, 2007
4. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
5. Shire plc: Correction Re Website
6. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
7. Shire Engages Palio
8. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
11. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 Yuma Regional ... and complementary therapies brings comprehensive cancer care to ... Yuma Regional Cancer Center has officially opened. A ... program includes services such as open, semi-private and ... American Cancer Society Resource Center, hematology, rehabilitation center, ...
(Date:7/30/2014)... Md. , July 30, 2014 ... components to interrogate biology, but such devices can ... As such, researchers have looked ... in vitro metabolic engineering to characterize ... a chip. New devices are envisioned to recreate ...
(Date:7/30/2014)... , July 30, 2014  RXi Pharmaceuticals ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that ... RXI-109, for the reduction of recurrence of ... has been initiated. Logo - ...
(Date:7/30/2014)... San Diego, CA (PRWEB) July 30, 2014 ... second contract from the U.S. Environmental Protection Agency ... company’s expertise in developmental toxicity models, including tests ... on neuron formation and the formation of connections ... function. Inhibition of neurodifferentiation and synapse formation by ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3
... in Series of Global Distribution Agreements to Make ... Available to Researchers Everywhere--ZyGEM Also Announces Issuance of ... SOLANA BEACH, Calif. and HAMILTON, New Zealand ... Corp. Ltd. today announced that it has entered ...
... May 28 GenVec, Inc. (Nasdaq: GNVC ... with a single institutional investor for the sale of 9,615,385 shares ... its common stock. The shares of common stock and warrants ... stock and a warrant to purchase one share of common stock ...
... the Chinese Academy of Sciences in Beijing, scientists have ... to understand how they may help in the development ... , The research focused on rotating magnetic fields, which ... and generators. The difficulty for technology at the atomic ...
Cached Biology Technology:ZyGEM Corp. Signs Agreement to Incorporate Its Breakthrough DNA Extraction Technology Into Rubicon's Research and Diagnostic Products 2ZyGEM Corp. Signs Agreement to Incorporate Its Breakthrough DNA Extraction Technology Into Rubicon's Research and Diagnostic Products 3ZyGEM Corp. Signs Agreement to Incorporate Its Breakthrough DNA Extraction Technology Into Rubicon's Research and Diagnostic Products 4GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants 2GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants 3
(Date:7/30/2014)... baboons suggests that the route to a higher rank is ... of supportive sisters. , A female baboon,s social status is ... of her mother - the higher the mother is ranked, ... rank in female baboons is thought to be determined at ... spot in the pecking order, whereas females born to low-ranking ...
(Date:7/30/2014)... 30, 2014 NexID Biometrics , ... detection solutions for the biometric authentication industry, has ... revolutionizing online authentication with standards for strong authentication. ... "The decision to join FIDO Alliance stems from ... in use. We believe the FIDO Alliance is ...
(Date:7/30/2014)... through a massive collection of 20-million-year-old amber found in ... the effort is yielding fresh insights into ancient tropical ... collection is fully curated, a task that will take ... amber collection in the world, the researchers report. ... that of a pygmy locust, a tiny grasshopper the ...
Breaking Biology News(10 mins):Supportive moms and sisters boost female baboon's rank 2Supportive moms and sisters boost female baboon's rank 3NexID Biometrics Joins the FIDO Alliance 2Decades-old amber collection offers new views of a lost world 2
... salmon make one heck of a commute. The record holder in ... in the Clearwater River, Idaho, in April 2003. A year and ... near Japan. The most direct route between those two points ... Imagine fish that make it that far then turn around and ...
... reduces illness severity and duration in children one ... hours of symptom onset, according to new data ... Disease (WISPID) meeting in Bangkok 15-18 November. The ... incidence of respiratory tract infections, ear infections and ...
... as one-third of global energy consumption. However, unconventional changes ... emissions. ETH Zurich Professor for Sociology, Dirk Helbing, has ... could improve vehicular traffic flow by up to 95 ... ETH Zurich Chair of Sociology, a specialist in modelling ...
Cached Biology News:UW launches cutting-edge DNA 'fin-printing' project for salmon 2UW launches cutting-edge DNA 'fin-printing' project for salmon 3Tamiflu effective for treatment and prevention of influenza in children 1 year and older 2Tamiflu effective for treatment and prevention of influenza in children 1 year and older 3Traffic control systems 2Traffic control systems 3Traffic control systems 4
Taq DNA Polymerase (cloned), 250 units. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Polymerases....
Request Info...
Request Info...
Candida (IgA) -Ab EIA Sample Size: 5 l...
Biology Products: